These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22761931)

  • 1. Aldosterone antagonists in monotherapy are protective against streptozotocin-induced diabetic nephropathy in rats.
    Banki NF; Ver A; Wagner LJ; Vannay A; Degrell P; Prokai A; Gellai R; Lenart L; Szakal DN; Kenesei E; Rosta K; Reusz G; Szabo AJ; Tulassay T; Baylis C; Fekete A
    PLoS One; 2012; 7(6):e39938. PubMed ID: 22761931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Na+,K+-ATPase is modulated by angiotensin II in diabetic rat kidney--another reason for diabetic nephropathy?
    Fekete A; Rosta K; Wagner L; Prokai A; Degrell P; Ruzicska E; Vegh E; Toth M; Ronai K; Rusai K; Somogyi A; Tulassay T; Szabo AJ; Ver A
    J Physiol; 2008 Nov; 586(22):5337-48. PubMed ID: 18818245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
    Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of O-linked N-acetylglucosamine modification in diabetic nephropathy.
    Gellai R; Hodrea J; Lenart L; Hosszu A; Koszegi S; Balogh D; Ver A; Banki NF; Fulop N; Molnar A; Wagner L; Vannay A; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1172-F1181. PubMed ID: 27029430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
    Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
    J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA; Gariani K; Martin PY
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
    Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
    Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
    Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
    Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
    Motawi TK; El-Maraghy SA; Senousy MA
    J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli.
    Xu ZG; Yoo TH; Ryu DR; Cheon Park H; Ha SK; Han DS; Adler SG; Natarajan R; Kang SW
    Kidney Int; 2005 Mar; 67(3):944-52. PubMed ID: 15698433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combining ACE inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis.
    Kramer AB; van der Meulen EF; Hamming I; van Goor H; Navis G
    Kidney Int; 2007 Mar; 71(5):417-24. PubMed ID: 17213874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
    Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
    Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired angiotensin II AT(1) receptor function and enhanced Na, K-ATPase affinity for sodium in proximal tubule of streptozotocin-treated diabetic rats.
    Siddiqui AH; Hussain T
    Clin Exp Hypertens; 2007 Oct; 29(7):435-44. PubMed ID: 17994353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes.
    Dong D; Fan TT; Ji YS; Yu JY; Wu S; Zhang L
    Int Urol Nephrol; 2019 Apr; 51(4):755-764. PubMed ID: 30734886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.